Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Integra LifeSciences Holdings Corporation

Citi analyst Joanne Wuensch maintained a Hold rating on Integra Lifesciences today and set a price target of $19.00. According to TipRanks, Wuensch...

Citi Keeps Their Hold Rating on Integra Lifesciences (IART)

In a report released today, Vik Chopra from BMO Capital maintained a Hold rating on Integra Lifesciences, with a price target of $18.00. According ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IART	$18.34	0.00%	795.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IART	$18.34	0%	795.11K
3
4
5
6

IART

Get Integra LifeSciences Holdings Corporation Data in Excel

Get Integra LifeSciences Holdings Corporation Data in Excel